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Abstract Women with heart disease are at risk of cardiac
complications during pregnancy and delivery. Risk assess-
ment should be performed in these women, and the
management of pregnancy and delivery should be planned
accordingly. Depending on the risk, women should be cared
for in specialised centres, regional centres or a combination
of both. Multidisciplinary teams must be involved in the
care of these women. Adequate organisation of care and
communication between the team members is important to
prevent complications.
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Introduction
Adult women with heart disease frequently pursue pregnancy.
Pregnancy induces haemodynamic changes, which include a
4 0 %i n c r e a s ei np l a s m av o l u m ea n dc a r d i a co u t p u ta sw e l la sa
marked reduction in systemic vascular resistance. Additionally
haemostatic changes lead to hypercoagulability. The physio-
logical changes of pregnancy are often well tolerated by
women with heart disease, but may also induce complications
such as heart failure, arrhythmias and thromboembolic events
[1–4]. The peripartum period constitutes an extra risk, since
during and after delivery cardiac demand increases due to
uterus contractions, anxiety, pushing, autotransfusion of the
contracting uterus post-delivery, and blood loss. The risk of
pregnancy should be assessed before and during pregnancy,
and management of pregnancy and delivery must be planned
accordingly [5, 6]. Adequate pregnancy management includes
involvement of a multidisciplinary team that ensures appro-
priate and well-organised care during pregnancy and peri-
partum. In the first article of this series, a system for risk
assessment was described [5]. This second article illustrates
that untoward complications can arise unexpectedly even in
women with heart disease who are at the favourable end of
the risk spectrum and it describes the requirements for the
management of pregnancy and delivery in order to prevent,
recognise and treat complications and guide these women
safely through this highly desired life event.
Case description and comment
A 28-year-old woman presented with a pregnancy wish. She
had a history of subvalvular membranous aortic stenosis. At 7
and at 14 years of age surgical resection of the membrane was
performed. As a young adult, she developed recurrent severe
subvalvular stenosis which became symptomatic. When she
was21yearsold,the membranewasradicallyresectedthrough
a Morrow procedure and the left ventricular (LV) outflow tract
was widened with a Konnoprocedure.Afterthis operationshe
was symptom-free and needed no medication. Her echocar-
diogram demonstrated septal akinesia with an LV diastolic
diameter of 57 mm at the basal level but a normal
midventricular diameter of 52 mm. LV ejection fraction was
50%. The aortic valve was abnormal with grade I regurgitation
andvalvularaorticstenosiswithpeakandmeangradientsof27
and 15 mmHg. It was concluded that she had a slightly
elevatedriskofheartfailureandarrhythmiasduringpregnancy
because of her mild aortic valve dysfunction and local wall
motion abnormality of the LV. She was graded as pregnancy
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pregnant in 2007 and was followed in the cardiac service at
20, 26 and 34 weeks. Her LV diameters and ejection fraction
as well as the aortic stenosis and regurgitation were stable.
She developed dyspnoea on exertion during the second
trimester without signs of heart failure, which was attributed
to the pregnancy in combination with moderate overweight.
During the last weeks of pregnancy she started to gain
weight, a total of 8 kg in 2 weeks time, and she felt more
dyspnoeic. The patient, a medical doctor herself, suggested
that she had fluid retention due to heart failure, but the junior
gynaecologist assured her that this weight gain was normal
and the cardiologist was not consulted. Delivery was induced
at 39 weeks and a healthy daughter was delivered by
secondary caesarean section. Two months after delivery she
was admitted because of bradycardia due to 2nd degree AV
block and a DDDR pacemaker was inserted. Unfortunately, at
the first echocardiogram after delivery her LV diameters were
significantly larger than pre-pregnancy, 65 and 58 mm at
basal and midventricular levels, respectively, with preserved
ejection fraction of 50%. She remained in NYHA class II
post-pregnancy. It was considered that she may have had an
unrecognised period of heart failure in the weeks before
delivery which was a likely explanation for the LV dilatation.
Alternatively, ventricular pacing may have caused the
dilatation post-pregnancy.
It can be concluded that the care of this woman was
suboptimal in the last weeks of her pregnancy. Her pregnancy
risk was adequately assessed as low to moderate, therefore
routine cardiac supervision was not planned after the 34th
week. However, the cardiologist should have been consulted
both when she complained of excessive weight gain and
increasing dyspnoea and when the delivery started. We can
only speculate if this would have made any difference in
outcome. Nevertheless, if she had been diagnosed with heart
failure,medicationand/orearlydeliverymighthaveprevented
damage. In the CEMACH (Confidential Enquiry on Maternal
Death) report [8], it appeared that substandard care was an
important contributing factor to the death of many mothers.
Substandard care included insufficient communication be-
tween team members and inappropriate delegation of tasks to
junior doctors. Though outcome was more favourable than in
the CEMACH report, these factors may have also played a
role in our case. Adequate organisation of care with skilled
multidisciplinary teams working according to standard
operating procedures is important to prevent unnecessary
complications.
Management of pregnancy
It is advisable that all women with cardiac disease have one
consultation in a specialised centre for counselling, risk
estimation and formulation of a management plan. This
should preferably take place before pregnancy, or otherwise
as early in pregnancy as possible. It should be decided
where the woman will receive cardiology and obstetric care
during pregnancy. Three levels of care can be distinguished.
These levels of care are comparable with the care
recommended in the ESC guidelines for the management
of grown-up congenital heart disease and are modified for
pregnant women with heart disease according to disease
complexity and pregnancy risk [9]. Level 1 represents care
for highly complex and high-risk (WHO class III or IV)
lesions, for which exclusive care in a specialist unit is
advisable, usually monthly or bimonthly. Level 2 represents
care for moderately complex lesions and low to moderate
risk of pregnancy (WHO II); these women can be managed
in a shared care model by collaboration of a specialist and a
regional cardiac and obstetric service and usually need
cardiac follow-up once per trimester. Women with simple
lesions and low pregnancy risk (WHO class I) are classified
for level 3 care which means that they can be managed
entirely in a regional hospital. For these women, cardiac
follow-up can be limited to once or twice during the
pregnancy. Examples are provided in Table 1.
When a woman uses medication, she needs to be advised
about the continuation, cessation or change of her medica-
tion before she gets pregnant. ACE inhibitors, angiotensin
II receptor blockers and statins are contraindicated through-
out pregnancy and must be discontinued, preferably before
pregnancy. Amiodarone should also be discontinued.
Vitamin K antagonists should be avoided in the first
trimester and be replaced by unfractionated heparin or
low-molecular-weight heparin. However, in women with
mechanical valves, continuation of vitamin K antagonists
can be considered, especially when daily dose requirements
are low, because of the higher risk of valve thrombosis with
heparins. Most β-blockers can be continued if necessary,
except atenolol. Also calcium antagonists appear to be well
tolerated and can be used during pregnancy when neces-
sary, though experience is limited [6, 10]. In all women
with a pregnancy wish or who are pregnant, thromboem-
bolic risk should be assessed according to the schedules
presented in the ESC guidelines for the management of
cardiovascular diseases during pregnancy [6], and when
applicable thromboprophylaxis and/or compression stock-
ings can be implemented when pregnancy occurs.
During pregnancy, standard cardiac follow-up for most
women will consist of clinical assessment and echocardi-
ography. Additionally depending on the underlying lesion
and on symptoms, 24-hour ECG monitoring can be
performed. Exercise testing should preferably be performed
pre-pregnancy to assist in risk estimation, but can be
performed in asymptomatic pregnant women to a heart rate
of 80% of the maximal predicted heart rate [6]. It is evident
34 Neth Heart J (2012) 20:33–37that radiation must be avoided if possible, but for vital
indications procedures involving radiation may be per-
formed, if no other possibilities are available. Radiation
exposure of the foetus is limited for most procedures and
acute foetal risk does not usually exist. Few data are
available to judge the safety of magnetic resonance imaging
during pregnancy, but it is probably safe at least after the
first trimester and provided gadolinium is avoided [11].
A multidisciplinary team should be involved in the
management of the pregnancy. The core members of this
team are the cardiologist and the gynaecologist, and when
delivery approaches the anaesthetist and neonatologist. For
some women a haematologist or a cardiac surgeon need to
be involved. It should never be forgotten that the general
practitioner is an important member of the team who should
be well informed about the course of the pregnancy, since
he may get involved at any stage of the pregnancy and
especially in emergency situations occurring outside the
hospital. A nurse practitioner can be a very useful member
of the team and can serve as the coordinator. Adequate
communication between team members is of paramount
importance. The cardiologist should formulate the cardiac
risks of the pregnancy and both cardiologist and gynaecol-
ogist must readily inform all team members about the
results of examinations and about complications that occur.
Management of delivery
At the end of the second trimester the multidisciplinary
team should formulate a plan for the delivery. This plan
should include:
– timing of delivery (spontaneous or induction)
– mode of delivery (vaginal delivery or caesarean
section)
– whether or not rhythm observation or haemodynamic
monitoring is necessary
– analgesia/anaesthesia
– advice about medication during delivery and lactation
– a plan for observation after delivery
Timing of delivery
Most women with heart disease can be allowed to go into
spontaneous labour [6]. Sometimes it may be preferable to
Table 1 Levels of care for pregnant women with heart disease
Level 1 Care in specialised centre Women with WHO risk class III or IV
a
Uncorrected cyanotic heart disease
Pulmonary hypertension/Eisenmenger syndrome
Dilatation of aorta
Severe mitral or aortic or pulmonary stenosis
Transposition of the great arteries
Fontan circulation
Ebstein’s disease
Dilated or hypertrophic cardiomyopathy
Mechanical valve prosthesis
Other corrected congenital heart disease with significant residual abnormalities
Level 2 Shared care, collaboration between
regional and specialised centre
Women with WHO risk class II
a
Mild or moderate mitral or aortic stenosis
Moderate mitral or aortic regurgitation
Moderate pulmonary stenosis
Corrected coarctation of aorta
b
Corrected atrioventricular septal defect
b
Corrected tetralogy of Fallot
b
Level 3 Care in regional centre Women with WHO class I
a
Small or repaired ventricular septal defect
Small or repaired atrial septal defect
Repaired ductus arteriosus
Mild pulmonary stenosis
Mild mitral or aortic regurgitation
aWHO risk class = World Health Organisation risk class for pregnant women with cardiac disease [2–4]
bIf no significant residual abnormalities
Neth Heart J (2012) 20:33–37 35induce delivery at a previously scheduled time, for example
in women with mechanical valves in order to be able to
manage anticoagulation more appropriately. In some women
early induced delivery may be preferred. This can be the case
for instance in women with heart failure or with progressive
aortic dilatation.
Mode of delivery
Severalstudiesshowthatcaesareansectionisperformedmore
ofteninwomenwithheartdiseasethaninahealthypopulation
[12, 13]. For most cardiac patients, however, vaginal
delivery is preferred and caesarean section is reserved for
obstetric indications, since caesarean section is associated
with more blood loss and higher thromboembolic and
infection risk. Examples of situations in which primary
caesarean section should be considered are start of labour
while on oral anticoagulants (because of risk of foetal
intracranial bleeding), Marfan syndrome with diameter of
the ascending aorta >45 mm, acute or chronic dissection, and
acute heart failure [6]. When vaginal delivery is chosen, it
should be decided whether the woman can be allowed to
push or if an assisted vaginal delivery is preferable. The
benefit of avoiding haemodynamic fluctuations resulting
from pushing must be weighed against an increased risk of
perineal trauma, haemorrhage and foetal head injury with
forceps or vacuum delivery. For most women, pushing may
be preferred above primary assisted delivery [14].
Rhythm observation and haemodynamic monitoring
Rhythm observation should be scheduled on an individual
basis in women with previous severe arrhythmias. Intra-
arterial pressure recording may be useful in women with
haemodynamic instability.
Analgesia/anaesthesia
Regional anaesthesia is often useful to reduce the cardiac
stress of vaginal delivery and is necessary for caesarean
delivery. Single-shot spinal anaesthesia can cause hypoten-
sion and should be avoided in cardiac patients with fixed
cardiac output or with shunting. Epidural, combined
epidural/spinal, and continuous spinal anaesthesia is safe
for most cardiac patients. However, caution remains
necessary to avoid excessive reduction in systemic vascular
resistance [6, 14].
Advice concerning medication
Administrationofoxytocinisusefultoreducehaemorrhage.It
should be given as a slow intravenous infusion and not as a
rapid bolus to avoid hypotension. When anticoagulation is
necessary, especially in women with mechanical valves,
warfarin or low-molecular-weight heparin should be replaced
by unfractionated heparin 36 h before induction of labour.
Unfractionated heparin should be discontinued 4–6 h before
deliveryandrestarted4–6hafterdelivery.Whenthemotheris
on chronic medication advice concerning lactation should be
formulated according to the new guidelines [6].
Observation after delivery
After delivery, haemodynamic changes occur due to caval
decompression and volume loading through autotransfu-
sion of blood from the contracting uterus. Therefore, the
risk of complications is increased. Discharge from hospital
should routinely be delayed until at least 24–7 2ha f t e r
delivery, depending on underlying heart disease and risk
estimation.
Conclusion
Women with heart disease need care from a multidisciplin-
ary team to guide them safely through pregnancy. Careful
management of pregnancy and delivery is required.
Adequate organisation of care and communication between
all professionals involved in the care of these women is of
paramount importance to prevent complications. The new
European Society of Cardiology guidelines on the manage-
ment of cardiovascular diseases during pregnancy [6]
provide the relevant medical information and recommen-
dations to assist multidisciplinary teams in their task.
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